SG11202103183PA - Agents and methods for modulating pathogen activity - Google Patents
Agents and methods for modulating pathogen activityInfo
- Publication number
- SG11202103183PA SG11202103183PA SG11202103183PA SG11202103183PA SG11202103183PA SG 11202103183P A SG11202103183P A SG 11202103183PA SG 11202103183P A SG11202103183P A SG 11202103183PA SG 11202103183P A SG11202103183P A SG 11202103183PA SG 11202103183P A SG11202103183P A SG 11202103183PA
- Authority
- SG
- Singapore
- Prior art keywords
- agents
- methods
- pathogen activity
- modulating
- modulating pathogen
- Prior art date
Links
- 230000000694 effects Effects 0.000 title 1
- 244000052769 pathogen Species 0.000 title 1
- 230000001717 pathogenic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A61K9/0039—Devices retained in the uterus for a prolonged period, e.g. intrauterine devices for contraception
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862739025P | 2018-09-28 | 2018-09-28 | |
| PCT/AU2019/051055 WO2020061649A1 (en) | 2018-09-28 | 2019-09-30 | Agents and methods for modulating pathogen activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202103183PA true SG11202103183PA (en) | 2021-04-29 |
Family
ID=69949189
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202103183PA SG11202103183PA (en) | 2018-09-28 | 2019-09-30 | Agents and methods for modulating pathogen activity |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210338685A1 (en) |
| EP (2) | EP3856196B1 (en) |
| KR (1) | KR20210069086A (en) |
| CN (1) | CN113164494B (en) |
| AU (1) | AU2019348194A1 (en) |
| BR (1) | BR112021005955A2 (en) |
| CA (2) | CA3224977A1 (en) |
| DK (1) | DK3856196T3 (en) |
| MX (1) | MX2021003730A (en) |
| SG (1) | SG11202103183PA (en) |
| WO (1) | WO2020061649A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111184707B (en) * | 2020-02-20 | 2021-04-27 | 中山大学 | Application of tolfenamic acid or pharmaceutically acceptable salt thereof in preparation of medicine for preventing and/or treating novel coronavirus inflammation |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2948718A (en) | 1960-08-09 | New n-heterocyclic compounds | ||
| US2554736A (en) | 1951-05-29 | Tertiary aminoalkyl-iminodibenzyls | ||
| US2868818A (en) | 1953-12-15 | 1959-01-13 | Merck & Co Inc | Alpha methyl phenylalanines |
| US3515785A (en) | 1958-12-06 | 1970-06-02 | Geigy Chem Corp | Compositions and methods for treating endogenous depression with 3-chloro - 5 - (gamma - dimethylamino - propyl)-iminodibenzyl |
| DE1142870B (en) | 1959-11-16 | 1963-01-31 | Geigy Ag J R | Process for the production of azepine derivatives |
| US3138636A (en) | 1960-06-23 | 1964-06-23 | Parke Davis & Co | Anthranilic acid derivatives |
| US3462536A (en) | 1960-07-22 | 1969-08-19 | Merck & Co Inc | Method of inhibiting decarboxylase |
| US3454554A (en) | 1960-10-14 | 1969-07-08 | Colgate Palmolive Co | Aminoalkyliminodibenzyl compounds |
| US3313848A (en) | 1964-06-18 | 1967-04-11 | Parke Davis & Co | Anthranilic acids and derivatives |
| FR1532301A (en) | 1967-01-18 | 1968-07-12 | Rhone Poulenc Sa | New derivatives of dibenzazepine and their preparation |
| CH500196A (en) | 1969-03-10 | 1970-12-15 | Ciba Geigy Ag | Process for the production of new azepine derivatives |
| US4092430A (en) | 1970-09-09 | 1978-05-30 | Ciba-Geigy Corporation | Antiphlogistic phenylacetohydroxamic acid compositions |
| US4692441A (en) * | 1985-08-16 | 1987-09-08 | Merck & Co., Inc. | Chorine esters as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal cavities |
| DE3811119C1 (en) | 1988-03-31 | 1989-10-12 | Merckle Gmbh, 7902 Blaubeuren, De | |
| IT1226902B (en) | 1988-07-12 | 1991-02-21 | Mini Ricerca Scient Tecnolog | LEVODOPA SYNTHESIS PROCESS |
| PT101732B (en) | 1995-06-30 | 1997-12-31 | Portela & Ca Sa | SUBSTITUTED AZEPINES PROCESS FOR THE PREPARATION OF THE PHARMACEUTICAL COMPOSITIONS CONTAINED THEREOF AND USES OF THE NEW COMPOUNDS IN THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS EMPLOYED IN DISEASES OF THE NERVOUS SYSTEM |
| AU7669496A (en) * | 1995-11-03 | 1997-05-22 | University Of Kentucky | Method for the intranasal administration of l-dopa prodrugs |
| IN190806B (en) | 1998-11-16 | 2003-08-23 | Max India Ltd | |
| DE19924148A1 (en) * | 1999-05-26 | 2000-12-07 | Univ Heidelberg | Sphingomyelinase inhibitors |
| US7261901B2 (en) * | 2001-01-31 | 2007-08-28 | University Of Iowa Research Foundation | Vaccine and compositions for the prevention and treatment of neisserial infections |
| WO2002060936A2 (en) | 2001-01-31 | 2002-08-08 | University Of Iowa Research Foundation | Vaccine and compositions for the prevention and treatment of neisserial infections |
| CA2437402A1 (en) | 2001-02-12 | 2002-08-22 | Teva Pharmaceutical Industries, Ltd. | New crystal forms of oxcarbazepine and processes for their preparation |
| AU2006239929B2 (en) * | 2005-04-22 | 2011-11-03 | Alantos Pharmaceuticals Holding, Inc. | Dipeptidyl peptidase-IV inhibitors |
| WO2008139484A2 (en) | 2007-05-16 | 2008-11-20 | R. L. Fine Chem | New process for the synthesis of loferpramine maleate: a stable salt of loferpramine |
| KR101141938B1 (en) * | 2010-01-22 | 2012-05-04 | 성균관대학교산학협력단 | Novel antibiotic compounds and methods for treating gram positive bacterial infections |
| TWI619494B (en) * | 2013-01-18 | 2018-04-01 | 華鴻新藥股份有限公司 | Compositions and methods of use of phorbol esters |
| EP3250194A4 (en) | 2015-01-26 | 2018-08-08 | Institute for Clinical Pharmacodynamics, Inc. | Method for shortening anti-infective therapy duration in subjects with infection |
| WO2017058735A1 (en) | 2015-09-28 | 2017-04-06 | Research Institute At Nationwide Children's Hospital | Compositions and methods for inhibiting the growth of neisseria gonorrhoeae |
| CN105949075B (en) | 2016-06-24 | 2017-11-07 | 江苏倍合德化工有限公司 | A kind of synthetic method of mefenamic acid |
| CN108309983B (en) * | 2018-01-15 | 2019-11-15 | 武汉百药联科科技有限公司 | Application of the carbamazepine in the drug of preparation treatment flavivirus infection |
| US11013707B2 (en) * | 2018-03-23 | 2021-05-25 | The Regents Of The University Of Colorado, A Body Corporate | Administration of oral methyldopa |
| CN108324716A (en) * | 2018-04-18 | 2018-07-27 | 日照市普达医药科技有限公司 | A kind of inverase and preparation method containing indinavir |
-
2019
- 2019-09-30 BR BR112021005955-5A patent/BR112021005955A2/en unknown
- 2019-09-30 MX MX2021003730A patent/MX2021003730A/en unknown
- 2019-09-30 CA CA3224977A patent/CA3224977A1/en active Pending
- 2019-09-30 US US17/280,603 patent/US20210338685A1/en active Pending
- 2019-09-30 AU AU2019348194A patent/AU2019348194A1/en active Pending
- 2019-09-30 EP EP19864039.3A patent/EP3856196B1/en active Active
- 2019-09-30 CA CA3115048A patent/CA3115048C/en active Active
- 2019-09-30 WO PCT/AU2019/051055 patent/WO2020061649A1/en active Search and Examination
- 2019-09-30 SG SG11202103183PA patent/SG11202103183PA/en unknown
- 2019-09-30 EP EP23209820.2A patent/EP4295864A3/en active Pending
- 2019-09-30 DK DK19864039.3T patent/DK3856196T3/en active
- 2019-09-30 CN CN201980078822.2A patent/CN113164494B/en active Active
- 2019-09-30 KR KR1020217012936A patent/KR20210069086A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN113164494A (en) | 2021-07-23 |
| CA3115048A1 (en) | 2020-04-02 |
| US20210338685A1 (en) | 2021-11-04 |
| WO2020061649A1 (en) | 2020-04-02 |
| KR20210069086A (en) | 2021-06-10 |
| EP4295864A2 (en) | 2023-12-27 |
| EP4295864A3 (en) | 2024-03-13 |
| EP3856196A1 (en) | 2021-08-04 |
| DK3856196T3 (en) | 2024-02-19 |
| CN113164494B (en) | 2024-08-27 |
| MX2021003730A (en) | 2021-06-18 |
| BR112021005955A2 (en) | 2021-07-27 |
| EP3856196A4 (en) | 2022-08-10 |
| CA3224977A1 (en) | 2020-04-02 |
| CA3115048C (en) | 2024-02-13 |
| EP3856196B1 (en) | 2023-11-15 |
| AU2019348194A1 (en) | 2021-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL271149A (en) | Compounds for modulating s1p1 activity and methods of using the same | |
| IL269462A (en) | Mdm2 inhibitors and therapeutic methods using the same | |
| GB201820166D0 (en) | Therapeutic agents | |
| IL286669A (en) | Compounds and methods for modulating tmprss6 expression | |
| IL271025A (en) | Multibiotic agents and methods of using the same | |
| GB201820165D0 (en) | Therapeutic agents | |
| IL285229A (en) | Compounds and methods for modulating rna function | |
| GB201709456D0 (en) | Therapeutic agents | |
| EP3534910A4 (en) | Therapeutic agents and methods | |
| IL273015A (en) | Agents modulating beta-catenin functions and methods thereof | |
| IL271728A (en) | Agents, uses and methods for treatment | |
| SG11202100352YA (en) | Interaction method and device | |
| GB201805816D0 (en) | Therapeutic agents | |
| IL287079A (en) | Compositions and methods for modulating complement activity | |
| GB201820088D0 (en) | Opitical devices and methods | |
| SG11202009940RA (en) | Device for creating track use plan, and method for creating track use plan | |
| EP3547934A4 (en) | Devices and methods for nerve regeneration | |
| SG11202110679YA (en) | Compounds and methods for modulating ube3a-ats | |
| GB201700553D0 (en) | Therapeutic agents | |
| SG11202103183PA (en) | Agents and methods for modulating pathogen activity | |
| IL272732A (en) | Activity modulator | |
| IL287709A (en) | Par2 modulation and methods thereof | |
| GB201820172D0 (en) | Therapeutic agents | |
| GB201820170D0 (en) | Therapeutic agents | |
| GB201820168D0 (en) | Therapeutic agents |